Great overview on respiratory motion management with thought-provoking data presented this morning by fantastic Marianne Aznar in #ESTROAsia2024 ESTRO - Advanced techniques pushed in large academic centres (to bepropagated) 🤞 - Remember that most signals are surrogates!

📌 Intrafraction motion in surface-guided breast radiotherapy, and its implications on a single PTV margin strategy. - Practical Radiation Oncology ⁦OncoAlert⁩ #OncoAlertAF practicalradonc.org/article/S1879-…

📌Laterality of Radiation Therapy in Breast Cancer is Not Associated With Increased Risk of Coronary Artery Disease in the Contemporary Era - Advances in Radiation Oncology advancesradonc.com/article/S2452-… ➡️ “data from patients diagnosed after 2010 within our institutional cohort did

📌 Radiation Therapy Followed by Intrathecal Trastuzumab- Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease A Phase 1 Nonrandomized Controlled Trial ja.ma/4fTb7pu OncoAlert #OncoAlertAF

Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms out on Cell Study presents a computational🖥️🔬 pathology platform for non-small cell #LungCancer 🫁 #NSCLC ) that aids in patient care optimization and

Catch the latest #BreastCancer insights from #ASCO24 NOW available FREE & ON DEMAND! Dive into highlights curated by VJ Oncology w/OncoAlert🚨Faculty Sara Tolaney 🇺🇸 G Curigliano MD PhD 🇮🇹& Erika Hamilton, MD 🇺🇸 LINK: bit.ly/46ocCYG ✅DB-06: T-DXd vs TPC for HR+ HER2-low or

Significance of HER2-Low in DCIS How might it impact on clinical practice in the foreseeable future? Knowledge that DCIS with low HER2 expression is associated with less aggressive features could inform less aggressive future therapeutic interventions clinical-breast-cancer.com/article/S1526-…

📌 Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights OncoAlert #OncoAlertAF ascopubs.org/doi/10.1200/OP…

👉🏻 OncoAlert 🚨 Newsletter NOW OUT Covering August 23-29 🗓️ Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale...📬📩 Discussing: ✅The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided

Two weeks until #ESMO24 We are OncoAlert REGISTER at oncoalert.m-pages.com/nhMpwe/oncoale…

Neoadjuvant Immunotherapy—From Trials to Practice out on JAMA Oncology by Dr. E Mittendorf and our @oncoAlert #BreastCancer Faculty Sara Tolaney of Dana-Farber 🇺🇸 Immunotherapy, particularly immune checkpoint♟️ inhibition, has become a key🔑component of #cancer treatment, with approvals

📌 Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early #BreastCancer A Systematic Review and Meta-Analysis. jamanetwork.com/journals/jamao… 👉🏻 In this meta-analysis involving 5114 patients neoadjuvant ICI therapy was associated with improved efficacy outcomes in

📌 Residual breast tissue after mastectomy and reconstruction: A substudy of the Spatial location of breast cancer local rECurRence aftEr masTectomy (SECRET) project 👉🏻 Different mastectomy procedures vary according to technique and extent of tissue removed. 👉🏻 The amount of

📌 BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. nature.com/articles/s4141… OncoAlert #OncoAlertAF

📌Caring for Your Heart During Cancer Treatment | Cardiology | JAMA Oncology | JAMA Network ⁦OncoAlert⁩ ⁦Eric K. Singhi, MD⁩ 👏🏻👏🏻#OncoAlertAF jamanetwork.com/journals/jamao…

🚨 ToP 🔟 Abtracts to be presented at #ESMO24 🇪🇸 by 🚨 OncoAlert #breastcancer

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 GI Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dr Joseph McCollom DO 🇺🇸 Erman Akkus 🇹🇷 Gil Morgan, MD 🇺🇸 1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty

📌 Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. nature.com/articles/s4152… 👉🏻 to evaluate the association of sTILs with progression-free survival in randomized